JP2015509973A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509973A5 JP2015509973A5 JP2014561515A JP2014561515A JP2015509973A5 JP 2015509973 A5 JP2015509973 A5 JP 2015509973A5 JP 2014561515 A JP2014561515 A JP 2014561515A JP 2014561515 A JP2014561515 A JP 2014561515A JP 2015509973 A5 JP2015509973 A5 JP 2015509973A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- formula
- composition according
- metal salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims 4
- 229910052751 metal Inorganic materials 0.000 claims 3
- 239000002184 metal Substances 0.000 claims 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000003381 stabilizer Substances 0.000 claims 3
- 239000013078 crystal Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- -1 (2-chlorobenzyl) -4-oxo-3,4-dihydroquinazolin-5-yl Chemical group 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 208000029771 childhood onset asthma Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 229940071138 stearyl fumarate Drugs 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261610023P | 2012-03-13 | 2012-03-13 | |
| US201261610012P | 2012-03-13 | 2012-03-13 | |
| US61/610,012 | 2012-03-13 | ||
| US61/610,023 | 2012-03-13 | ||
| PCT/GB2013/050624 WO2013136076A1 (en) | 2012-03-13 | 2013-03-13 | Crystalline pi3 kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017151378A Division JP2018008992A (ja) | 2012-03-13 | 2017-08-04 | 結晶性ｐｉ３キナーゼ阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015509973A JP2015509973A (ja) | 2015-04-02 |
| JP2015509973A5 true JP2015509973A5 (https=) | 2016-04-14 |
Family
ID=49160309
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014561515A Pending JP2015509973A (ja) | 2012-03-13 | 2013-03-13 | 結晶性ｐｉ３キナーゼ阻害剤 |
| JP2014561514A Expired - Fee Related JP6189874B2 (ja) | 2012-03-13 | 2013-03-13 | 新規製薬学的製剤 |
| JP2017151378A Withdrawn JP2018008992A (ja) | 2012-03-13 | 2017-08-04 | 結晶性ｐｉ３キナーゼ阻害剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014561514A Expired - Fee Related JP6189874B2 (ja) | 2012-03-13 | 2013-03-13 | 新規製薬学的製剤 |
| JP2017151378A Withdrawn JP2018008992A (ja) | 2012-03-13 | 2017-08-04 | 結晶性ｐｉ３キナーゼ阻害剤 |
Country Status (35)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
| UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
| NZ628072A (en) | 2012-03-13 | 2015-08-28 | Respivert Ltd | Crystalline pi3 kinase inhibitors |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US9737521B2 (en) | 2012-11-08 | 2017-08-22 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor |
| US9227977B2 (en) | 2013-03-15 | 2016-01-05 | Respivert Ltd. | Phosphoinositide 3-kinase inhibitors |
| JO3279B1 (ar) | 2013-03-15 | 2018-09-16 | Respivert Ltd | مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| MX2021012208A (es) | 2013-10-04 | 2023-01-19 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos y usos de los mismos. |
| NZ724368A (en) | 2014-03-19 | 2023-07-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| MX2017000208A (es) | 2014-07-04 | 2017-05-01 | Lupin Ltd | Derivados de quinolizinona como inhibidores de pi3k. |
| ES2701525T3 (es) * | 2014-07-09 | 2019-02-22 | Arven Ilac Sanayi Ve Ticaret As | Un procedimiento para la preparación de formulaciones para inhalación |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP4585268A3 (en) | 2015-09-14 | 2025-10-15 | Twelve Therapeutics, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
| EP3443954B1 (en) * | 2016-04-15 | 2026-02-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Inhaled preparation of magnesium isoglycyrrhizinate and use thereof for treating respiratory system diseases and chronic viral hepatitis |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1204826B (it) | 1986-03-04 | 1989-03-10 | Chiesi Farma Spa | Composizioni farmaceutiche per inalazione |
| GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| WO1999028979A2 (en) | 1997-12-02 | 1999-06-10 | Alcatel Usa Sourcing, L.P. | Digital phone system |
| AU756852B2 (en) | 1998-11-13 | 2003-01-23 | Jagotec Ag | Dry powder for inhalation |
| DK1140938T3 (da) | 1999-01-11 | 2003-12-22 | Univ Princeton | Højaffinitetsinhibitorer for målvalidering og anvendelser heraf |
| ES2286881T3 (es) | 1999-03-05 | 2007-12-01 | Chiesi Farmaceutici S.P.A. | Composiciones farmaceuticas en polvo mejoradas para inhalacion. |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| CN1186324C (zh) | 2000-04-27 | 2005-01-26 | 山之内制药株式会社 | 稠合杂芳基衍生物 |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| WO2003006628A2 (en) | 2001-07-13 | 2003-01-23 | Virtual Drug Development, Inc. | Nad synthetase inhibitors and uses thereof |
| WO2003007955A2 (en) | 2001-07-20 | 2003-01-30 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
| US20040132732A1 (en) | 2002-10-21 | 2004-07-08 | Wei Han | Quinazolinones and derivatives thereof as factor Xa inhibitors |
| WO2004080966A1 (ja) | 2003-03-14 | 2004-09-23 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| US7122557B2 (en) | 2003-03-18 | 2006-10-17 | Bristol-Myers Squibb Company | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors |
| EP1625165A2 (en) | 2003-04-03 | 2006-02-15 | Protein Design Labs, Inc. | Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation |
| US7429596B2 (en) | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
| JP2009513529A (ja) | 2003-07-11 | 2009-04-02 | グラクソ グループ リミテッド | ステアリン酸マグネシウムを含む医薬製剤 |
| GB0316341D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Pharmaceutical formulations |
| EP1661879A4 (en) | 2003-08-04 | 2006-11-29 | Ono Pharmaceutical Co | A DIPHENYL ETHER COMPOUND, PROCESS FOR THE PRODUCTION AND USE THEREOF |
| WO2005016348A1 (en) | 2003-08-14 | 2005-02-24 | Icos Corporation | Method of inhibiting immune responses stimulated by an endogenous factor |
| US20050054614A1 (en) | 2003-08-14 | 2005-03-10 | Diacovo Thomas G. | Methods of inhibiting leukocyte accumulation |
| GB0326632D0 (en) | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
| US20050239809A1 (en) | 2004-01-08 | 2005-10-27 | Watts Stephanie W | Methods for treating and preventing hypertension and hypertension-related disorders |
| CA2730540A1 (en) | 2004-05-13 | 2005-12-01 | Vanderbilt University | Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis |
| SI2612862T1 (sl) | 2004-05-13 | 2017-04-26 | Icos Corporation | Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta |
| JP2008500338A (ja) | 2004-05-25 | 2008-01-10 | イコス・コーポレイション | 造血細胞の異常増殖を治療及び／又は予防する方法 |
| CA2569406A1 (en) | 2004-06-04 | 2005-12-22 | Icos Corporation | Methods for treating mast cell disorders |
| EP1790637B1 (en) | 2004-09-13 | 2014-01-29 | Ono Pharmaceutical Co., Ltd. | Derivatives of N-4-piperidyl urea and medicaments containing them as active ingredient |
| GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| WO2006089106A2 (en) | 2005-02-17 | 2006-08-24 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
| GB0525254D0 (en) | 2005-12-12 | 2006-01-18 | Jagotec Ag | Powder compositions for inhalation |
| SI2004654T1 (sl) * | 2006-04-04 | 2013-11-29 | The Regents Of The University Of California | Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti |
| WO2007114926A2 (en) | 2006-04-04 | 2007-10-11 | The Regents Of The University Of California | Kinase antagonists |
| CA2652886A1 (en) | 2006-05-24 | 2007-11-29 | Bayer Schering Pharma Aktiengesellschaft | High affinity human and humanized anti-.alpha.5.beta.1 integrin function blocking antibodies with reduced immunogenicity |
| EP2032560B1 (en) | 2006-06-29 | 2013-05-01 | Merck Sharp & Dohme Corp. | Substituted bicyclic and tricyclic thrombin receptor antagonists |
| GB0622818D0 (en) | 2006-11-15 | 2006-12-27 | Jagotec Ag | Improvements in or relating to organic compounds |
| CA2668744C (en) | 2006-11-17 | 2015-09-15 | Queen's University At Kingston | Compounds and methods for treating protein folding disorders |
| WO2008067219A2 (en) | 2006-11-29 | 2008-06-05 | Kalypsys, Inc. | Quinazolinone modulators of tgr5 |
| US8338437B2 (en) | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
| CA2684932A1 (en) * | 2007-05-09 | 2008-11-20 | Novartis Ag | Substituted imidazopyridazines as pi3k lipid kinase inhibitors |
| WO2008140750A1 (en) | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
| EP3613743B1 (en) | 2008-01-04 | 2022-03-16 | Intellikine, LLC | Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives |
| US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
| WO2010059593A1 (en) | 2008-11-18 | 2010-05-27 | Intellikine, Inc. | Methods and compositions for treatment of ophthalmic conditions |
| AU2009322187B2 (en) | 2008-12-04 | 2015-02-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of CNS disorders |
| US8658648B2 (en) | 2008-12-05 | 2014-02-25 | Designmedix, Inc. | Modified chloroquines with single ring moiety or fused ring moiety |
| US20110135655A1 (en) | 2009-01-13 | 2011-06-09 | PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; | Role of PI3K p110 delta Signaling in Retroviral Infection and Replication |
| CA2756347A1 (en) | 2009-03-24 | 2010-09-30 | Gilead Calistoga Llc | Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use |
| MX2012001504A (es) | 2009-08-05 | 2012-06-01 | Versitech Ltd | Compuestos antivirales y metodos para elaborarlos y usarlos. |
| GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
| WO2011083387A1 (en) | 2010-01-07 | 2011-07-14 | Pfizer Limited | Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester |
| CN201676365U (zh) * | 2010-03-29 | 2010-12-22 | 山东京卫制药有限公司 | 带有语音提示的给药吸入装置 |
| CN201692450U (zh) * | 2010-06-22 | 2011-01-05 | 于清 | 用于药物输送的高效干粉吸入器 |
| AU2011298315B2 (en) | 2010-08-31 | 2014-08-28 | Glaxo Group Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
| CN103298470B (zh) | 2010-09-30 | 2015-06-17 | 奇斯药制品公司 | 硬脂酸镁在吸入用干粉制剂中的用途 |
| UY33337A (es) * | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
| CN202154919U (zh) * | 2011-05-03 | 2012-03-07 | 王晓明 | 一种防交叉感染雾化吸入装置 |
| NZ628072A (en) | 2012-03-13 | 2015-08-28 | Respivert Ltd | Crystalline pi3 kinase inhibitors |
-
2013
- 2013-03-13 NZ NZ628072A patent/NZ628072A/en not_active IP Right Cessation
- 2013-03-13 EP EP13711105.0A patent/EP2834244B1/en active Active
- 2013-03-13 CN CN201380013848.1A patent/CN104284679B/zh not_active Expired - Fee Related
- 2013-03-13 PE PE2014001414A patent/PE20141964A1/es not_active Application Discontinuation
- 2013-03-13 UA UAA201408662A patent/UA115544C2/uk unknown
- 2013-03-13 JP JP2014561515A patent/JP2015509973A/ja active Pending
- 2013-03-13 EP EP13711104.3A patent/EP2825202B1/en active Active
- 2013-03-13 IN IN2000MUN2014 patent/IN2014MN02000A/en unknown
- 2013-03-13 PE PE2014001415A patent/PE20142342A1/es not_active Application Discontinuation
- 2013-03-13 KR KR1020147026258A patent/KR20140141596A/ko not_active Ceased
- 2013-03-13 DK DK13711105.0T patent/DK2834244T3/en active
- 2013-03-13 US US14/381,273 patent/US20150099768A1/en not_active Abandoned
- 2013-03-13 CN CN201380013851.3A patent/CN104302650B/zh not_active Expired - Fee Related
- 2013-03-13 JP JP2014561514A patent/JP6189874B2/ja not_active Expired - Fee Related
- 2013-03-13 IN IN1998MUN2014 patent/IN2014MN01998A/en unknown
- 2013-03-13 MY MYPI2014702576A patent/MY171125A/en unknown
- 2013-03-13 TW TW102108766A patent/TWI586378B/zh not_active IP Right Cessation
- 2013-03-13 LT LTEP13711105.0T patent/LT2834244T/lt unknown
- 2013-03-13 CA CA 2864643 patent/CA2864643A1/en not_active Abandoned
- 2013-03-13 AU AU2013234081A patent/AU2013234081B2/en not_active Ceased
- 2013-03-13 NZ NZ627963A patent/NZ627963A/en not_active IP Right Cessation
- 2013-03-13 PT PT137111050T patent/PT2834244T/pt unknown
- 2013-03-13 CA CA 2864652 patent/CA2864652A1/en not_active Abandoned
- 2013-03-13 AU AU2013234080A patent/AU2013234080B2/en not_active Ceased
- 2013-03-13 SG SG11201404522VA patent/SG11201404522VA/en unknown
- 2013-03-13 HU HUE13711105A patent/HUE029420T2/en unknown
- 2013-03-13 WO PCT/GB2013/050623 patent/WO2013136075A1/en not_active Ceased
- 2013-03-13 SI SI201330362A patent/SI2834244T1/sl unknown
- 2013-03-13 PL PL13711105T patent/PL2834244T3/pl unknown
- 2013-03-13 HR HRP20161383TT patent/HRP20161383T1/hr unknown
- 2013-03-13 ES ES13711104.3T patent/ES2650791T3/es active Active
- 2013-03-13 TW TW102108767A patent/TWI617561B/zh not_active IP Right Cessation
- 2013-03-13 EA EA201491674A patent/EA025465B1/ru not_active IP Right Cessation
- 2013-03-13 US US14/381,289 patent/US9642799B2/en not_active Expired - Fee Related
- 2013-03-13 ES ES13711105.0T patent/ES2600705T3/es active Active
- 2013-03-13 WO PCT/GB2013/050624 patent/WO2013136076A1/en not_active Ceased
- 2013-03-13 KR KR1020147026305A patent/KR20140131971A/ko not_active Ceased
- 2013-03-13 SG SG11201404519UA patent/SG11201404519UA/en unknown
- 2013-03-13 EA EA201491675A patent/EA023715B1/ru not_active IP Right Cessation
- 2013-03-13 MX MX2014010990A patent/MX357170B/es active IP Right Grant
- 2013-03-13 MX MX2014010991A patent/MX355299B/es active IP Right Grant
-
2014
- 2014-07-30 PH PH12014501713A patent/PH12014501713A1/en unknown
- 2014-07-30 IL IL233883A patent/IL233883A0/en unknown
- 2014-07-30 IL IL233886A patent/IL233886A/en not_active IP Right Cessation
- 2014-08-27 PH PH12014501922A patent/PH12014501922A1/en unknown
- 2014-08-29 CO CO14190111A patent/CO7051030A2/es unknown
- 2014-08-29 CO CO14190112A patent/CO7061079A2/es unknown
- 2014-09-01 GT GT201400182A patent/GT201400182A/es unknown
- 2014-09-02 GT GT201400183A patent/GT201400183A/es unknown
- 2014-09-05 NI NI201400100A patent/NI201400100A/es unknown
- 2014-09-05 NI NI201400101A patent/NI201400101A/es unknown
- 2014-09-09 CL CL2014002385A patent/CL2014002385A1/es unknown
- 2014-09-09 CL CL2014002386A patent/CL2014002386A1/es unknown
- 2014-09-10 CR CR20140417A patent/CR20140417A/es unknown
- 2014-09-10 EC ECIEPI201418142A patent/ECSP14018142A/es unknown
- 2014-09-10 CR CR20140416A patent/CR20140416A/es unknown
- 2014-09-12 EC ECIEPI201418630A patent/ECSP14018630A/es unknown
- 2014-10-10 ZA ZA2014/07373A patent/ZA201407373B/en unknown
- 2014-10-10 ZA ZA2014/07374A patent/ZA201407374B/en unknown
-
2016
- 2016-11-09 CY CY20161101148T patent/CY1118565T1/el unknown
-
2017
- 2017-05-08 US US15/588,845 patent/US20170239256A1/en not_active Abandoned
- 2017-08-04 JP JP2017151378A patent/JP2018008992A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015509973A5 (https=) | ||
| HRP20161383T1 (hr) | Kristalni inhibitori pi3 kinaze | |
| JP2015509972A5 (https=) | ||
| JP2014524442A5 (https=) | ||
| JP2016537346A5 (https=) | ||
| JP2013541592A5 (https=) | ||
| RU2015132371A (ru) | Твердые формы селективного ингибитора CDK4/6 | |
| JP2018534348A5 (https=) | ||
| JP2017527549A5 (https=) | ||
| JP2015509534A5 (https=) | ||
| JP2013139446A5 (https=) | ||
| JP2017160243A (ja) | ７−｛（３ｓ、４ｓ）−３−［（シクロプロピルアミノ）メチル］−４−フルオロピロリジン−１−イル｝−６−フルオロ−１−（２−フルオロエチル）−８−メトキシ−４−オキソ−１、４−ジヒドロキノリン−３−カルボン酸の結晶 | |
| JP2016503010A5 (https=) | ||
| JP2015522037A5 (https=) | ||
| JP2015078201A5 (https=) | ||
| JP2013538849A5 (https=) | ||
| EP3283491A1 (en) | New forms of ixazomib citrate | |
| JP2016510768A5 (https=) | ||
| JP2022160667A (ja) | アクリジニウム臭化物の製造方法 | |
| JP2020528057A (ja) | ビランテロールトリフェニル酢酸塩の新規な結晶形態及びこれらの調製プロセス | |
| JP2017507980A5 (https=) | ||
| JP2018515527A5 (https=) | ||
| JP2016172741A5 (https=) | ||
| HRP20250660T1 (hr) | Čvrsti oblici ixazomib citrata | |
| JP2012530118A5 (https=) |